Compare PRAX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | HLI |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.6B |
| IPO Year | 2020 | 2015 |
| Metric | PRAX | HLI |
|---|---|---|
| Price | $337.29 | $150.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $572.13 | $194.29 |
| AVG Volume (30 Days) | 326.2K | ★ 441.1K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | N/A | ★ 41.61 |
| EPS | N/A | ★ 4.74 |
| Revenue | N/A | ★ $2,389,416,000.00 |
| Revenue This Year | N/A | $13.77 |
| Revenue Next Year | $7,758.26 | $12.10 |
| P/E Ratio | ★ N/A | $32.38 |
| Revenue Growth | N/A | ★ 24.81 |
| 52 Week Low | $34.89 | $134.41 |
| 52 Week High | $354.87 | $211.78 |
| Indicator | PRAX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 42.12 |
| Support Level | $282.49 | $135.21 |
| Resistance Level | $353.83 | $196.66 |
| Average True Range (ATR) | 18.75 | 3.46 |
| MACD | -0.96 | -0.83 |
| Stochastic Oscillator | 69.67 | 16.94 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.